Managers / Q4 2019 · view latest →
Canaan Partners X LLC
CIK 0001673228 · 2765 SAND HILL ROAD, MENLO PARK, CA, 94025 · 6508548092
Summary
Canaan Partners X LLC reported $155M in U.S.-listed holdings across 3 positions for Q4 2019.
The portfolio is heavily concentrated: Nextcure alone accounts for 82.1% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 95.0% · $147M
- Other · 5.0% · $8M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NextCure Inc | NEW | +2.25M | 2.25M | +$127M | $127M |
| IDYAIDEAYA Biosciences Inc | NEW | +2.66M | 2.66M | +$20M | $20M |
| Iterum Therapeutics plc | NEW | +1.73M | 1.73M | +$8M | $8M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NextCure Inc | COM | 82.06% | $127M | 2.25M |
| 2 | IDYAIDEAYA Biosciences Inchistory → | COM | 12.90% | $20M | 2.66M |
| 3 | Iterum Therapeutics plc | SHS | 5.04% | $8M | 1.73M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2023 | $75M | 2 | Oct 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $84M | 3 | Jul 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $56M | 2 | Apr 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $57M | 2 | Feb 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $64M | 3 | Oct 31, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $58M | 4 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $98M | 4 | Apr 28, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $257M | 4 | Feb 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $351M | 5 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $67M | 3 | Jul 22, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $73M | 3 | May 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $48M | 3 | Feb 2, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $50M | 3 | Oct 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $83M | 3 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $91M | 3 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $155M | 3 | Jan 27, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.